Retour au portail Europarl

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (sélectionné)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Ce document n'est pas disponible dans votre langue. Il vous est proposé dans une autre langue parmi celles disponibles dans la barre des langues.

Parliamentary questions
PDF 8kWORD 30k
16 April 2018
E-001276/2018(ASW)
Answer given by Mr Moedas on behalf of the Commission
Question reference: E-001276/2018

Under the Seventh Framework Programme for Research, Technological Development and Demonstration Activities (FP7, 2007-2013), several research projects(1) related to Lyme disease were funded with a total EU contribution of EUR 6 320 836.33. Under Horizon 2020, the EU Framework Programme for Research and Innovation (2014-2020), two research projects(2) related to Lyme disease have been funded so far with a total EU contribution of EUR 5 421 440.13. In addition, in 2016, the European Investment Bank granted EUR 25 million for the development of a Lyme vaccine(3) under the InnovFin MidCap Growth Finance(4) — EU Finance for Innovators programme(5).

The remaining two years of Horizon 2020, and in particular its forthcoming calls for research and innovation project proposals accessible via the Horizon 2020 Participant Portal(6), will offer further opportunities to support research on Lyme disease.

The Commission is working closely with the European Centre for Disease Prevention and Control (ECDC)(7), which has been organising expert meetings on Lyme disease, and published a systematic literature review on the diagnostic accuracy of serological tests for Lyme borreliosis in 2016(8),(9).

(1)EpiFor, COSEATIBO, HILYSENS, RICYSTVACANT20, ANTIDotE, Hilysens II.
(2)ID-Lyme and DualDur.
(3)http://www.eib.org/infocentre/press/releases/all/2016/2016-169-la-bei-accorde-un-pret-de-25-meur-a-valneva-pour-financer-ses-activites-de-r-d.htm
(4)http://www.eib.org/attachments/thematic/innovfin_midcap_growth_finance_en.pdf
(5)http://www.eib.org/infocentre/publications/all/innovfin-midcap-growth-finance.htm
(6)http://ec.europa.eu/research/participants/portal/desktop/en/home.html
(7)https://ecdc.europa.eu/en/home
(8)https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/lyme-borreliosis-diagnostic-accuracy-serological-tests-systematic-review.pdf
(9)https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-016-1468-4

Dernière mise à jour: 16 avril 2018Avis juridique